Research & Development Committee, Agenzia Italiana del Farmaco (AIFA), Roma, Italy.
Eur J Clin Invest. 2010 Jan;40(1):69-86. doi: 10.1111/j.1365-2362.2009.02226.x.
Key points * National Health Service (NHS) is becoming increasingly aware of the need to support independent research to answer some important questions for patient care in areas of scant commercial interest. * This article reports the main features and strategies of the independent research programme on drugs launched by the Italian Medicines Agency (AIFA) in 2005. * In the three bids launched between 2005 and 2007, a total of 151 studies have been approved for funding for a total of about 78 million Euro. * In this article we describe the Italian legislative framework under which the programme was launched, the types of research funded and discuss how the supported studies could contribute, in an international framework, to the knowledge needed on drug efficacy, effectiveness and safety.
要点 * 英国国家医疗服务体系(NHS)越来越意识到需要支持独立研究,以回答一些在商业利益微薄的领域中对患者护理至关重要的问题。* 本文报告了意大利药品管理局(AIFA)于 2005 年启动的药物独立研究计划的主要特点和策略。* 在 2005 年至 2007 年期间发起的三项招标中,共批准了 151 项研究以供资助,总计约 7800 万欧元。* 在本文中,我们描述了计划启动的意大利立法框架、资助的研究类型,并讨论了支持的研究如何能够在国际框架内为药物疗效、有效性和安全性所需的知识做出贡献。